The vaccine proves safe in a small sample of human subjects, opening the way for the next phase of testing
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation — an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases. Further tests to determine if the vaccine is effective at slowing tumor growth are forthcoming.
The results were published in the Journal for ImmunoTherapy of Cancer.
Colon cancer, especially in younger people, is on the rise and is currently the second highest cause of cancer deaths in the US and worldwide. Surgery can cure the disease in many patients, but prognosis is poor for those with recurrence of their disease. If it proves effective in larger-scale trials the vaccine, developed by researchers at Jefferson (Philadelphia University + Thomas Jefferson University), could train the patient’s immune system to attack the colon cancer that had already spread before the surgery.
“There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type. This is a true milestone– made possible through the scientists and clinicians in our colorectal cancer team working in synchrony”, said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center — Jefferson Health.
In earlier preclinical work in mice, Jefferson researchers demonstrated how the design of their vaccine worked. Tumor vaccines have historically been developed against a sort of molecular sign-post for cancer. Because they come from normal cells, cancer cells share nearly all of the same molecules, making it difficult for the immune system to differentiate normal from cancerous. Tumor antigens are molecules that the immune system can recognize as different from normal. In colorectal cancer, one such molecule called GUCY2C, was identified by Scott Waldman, MD, PhD, the Samuel M.V. Hamilton Professor and Director of the Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center — Jefferson Health.
The vaccine developed by first author, Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics, Dr. Waldman and others, works by activating the immune system against the GUCY2C molecule. By joining the GUCY2C molecule with a molecule that boosts the immune reaction called PADRE, and loading it into an adenovirus vector, the researchers engineered a vaccine that could specifically target the colon cancer.
The current clinical trial enrolled 10 patients with stage I or II colon cancer. Patients were given one dose and came back for blood draws 30, 90, 180 days after immunization. Patients experienced some discomfort at the injection site, but reported no serious side effects of the vaccine. The blood samples showed activation of “killer T cells,” the immune cell type the researchers had expected. These killer T cells are responsible for finding and killing colon cancer cells that are responsible for causing the cancer to come back.
“We are preparing for a phase II study that will begin recruiting patients this fall,” says Dr. Snook. “We used lessons learned in the first study to modify the vaccine to hopefully make it even more effective.”
Since starting the trial, the researchers found that cancers other than colorectal cancer also express GUCY2C, including gastric, esophageal and pancreatic cancer. These are actually among the deadliest cancers. In fact, together with colorectal cancer, these four cancer types account for 20 percent of all cancer-related deaths.
“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” says Dr. Snook.
The Latest on: Colorectal cancer vaccine
[google_news title=”” keyword=”colorectal cancer vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Colorectal cancer vaccine
- Great news: Biontech set to revolutionize cancer treatmenton November 27, 2023 at 3:28 am
According to ZDF, Biontech CEO Ugur Sahin has announced that the company is on track to develop a cancer vaccine by 2030. This innovative vaccine will be a significant leap forward in cancer treatment ...
- Outlining Novel Cellular Adjuvant Products for Therapeutic Vaccines Against Canceron November 26, 2023 at 4:01 pm
These formulations and combinations are under evaluation for a wide range of vaccine candidates in clinical trials. Here we describe cancer vaccine candidates using MPL adjuvant in the most ...
- Vaccines Newson November 26, 2023 at 4:01 pm
Nanoparticle Vaccine Could Curb Cancer Metastasis to Lungs by Targeting a Protein Oct. 18, 2023 — Engineers have developed an experimental vaccine that could prevent the spread of metastatic ...
- A breakthrough in cancer vaccines may be coming, and Houston is a hub for clinical trialson November 24, 2023 at 10:14 am
Houston serves as a hub for much of that research, as hospitals in the Texas Medical Center are participating in numerous clinical trials for cancer vaccine candidates. Decker said it’s thrilling to ...
- New Phase 1 Findings Show Promise of Cancer Vaccines in KRAS Mutationson November 23, 2023 at 12:00 pm
In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.
- A Cancer Vaccine? Scientists are Working on Iton November 22, 2023 at 2:00 am
One of the most exciting developments are cancer vaccines. Scientists are using artificial intelligence to identify mutations in cancerous tumors that the immune system can recognize, then ...
- Cancer vaccines: between the idea and the realityon November 21, 2023 at 11:42 pm
If, for example, a vaccine is to be used for the prevention of polyps as a means of preventing colon cancer, this vaccine will have to stimulate the type of immunity that can recognize and react ...
- 5 Cancer Vaccines to Watch in 2024on November 19, 2023 at 9:21 pm
BioSpace takes a deep dive into five investigational therapeutic cancer vaccines that have recently shown efficacy in difficult-to-treat indications.
- Research into targeted treatments, better prediction models in breast cancer fundedon November 16, 2023 at 11:57 am
Five Fred Hutchinson/University of Washington/Seattle Children’s Cancer Consortium researchers received additional funding from the Breast Cancer Research Foundation to continue ongoing research.
- Nouscom raises $72m in Series C financing round to develop cancer vaccineson November 14, 2023 at 9:49 am
Swiss biotech Nouscom has raised €67.5m ($72m) in a Series C funding round co-led by Andera Partners, Bpifrance and M Ventures. Revelation Partners, Indaco Venture Partners, Panakès Partners, X-Gen ...
via Bing News